Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Holdings Lessened by Cognios Beta Neutral Large Cap Fund LP

Cognios Beta Neutral Large Cap Fund LP trimmed its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.0% during the fourth quarter, HoldingsChannel.com reports. The fund owned 678 shares of the biopharmaceutical company’s stock after selling 67 shares during the period. Cognios Beta Neutral Large Cap Fund LP’s holdings in Regeneron Pharmaceuticals were worth $595,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the stock. Meyer Handelman Co. raised its position in Regeneron Pharmaceuticals by 11.4% during the third quarter. Meyer Handelman Co. now owns 4,235 shares of the biopharmaceutical company’s stock valued at $3,485,000 after buying an additional 435 shares during the period. Stifel Financial Corp raised its holdings in shares of Regeneron Pharmaceuticals by 12.2% during the third quarter. Stifel Financial Corp now owns 31,030 shares of the biopharmaceutical company’s stock worth $25,537,000 after acquiring an additional 3,385 shares in the last quarter. LPL Financial LLC boosted its position in Regeneron Pharmaceuticals by 9.3% during the third quarter. LPL Financial LLC now owns 40,733 shares of the biopharmaceutical company’s stock valued at $33,522,000 after purchasing an additional 3,479 shares during the last quarter. Cavalier Investments LLC grew its stake in Regeneron Pharmaceuticals by 88.6% in the third quarter. Cavalier Investments LLC now owns 4,436 shares of the biopharmaceutical company’s stock valued at $3,651,000 after purchasing an additional 2,084 shares in the last quarter. Finally, Exchange Traded Concepts LLC increased its position in Regeneron Pharmaceuticals by 32.7% in the 4th quarter. Exchange Traded Concepts LLC now owns 4,954 shares of the biopharmaceutical company’s stock worth $4,351,000 after purchasing an additional 1,221 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages recently commented on REGN. UBS Group boosted their price target on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a research note on Wednesday, April 17th. Truist Financial restated a “buy” rating and set a $1,135.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, April 3rd. Sanford C. Bernstein initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 price objective for the company. Royal Bank of Canada restated an “outperform” rating and set a $1,189.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 9th. Finally, Barclays boosted their price target on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 23rd. One research analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $977.77.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 827 shares of the firm’s stock in a transaction dated Tuesday, January 30th. The shares were sold at an average price of $959.00, for a total value of $793,093.00. Following the completion of the sale, the director now owns 1,382 shares in the company, valued at approximately $1,325,338. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $954.22, for a total transaction of $95,422.00. Following the transaction, the director now owns 18,382 shares of the company’s stock, valued at $17,540,472.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bonnie L. Bassler sold 827 shares of the business’s stock in a transaction dated Tuesday, January 30th. The stock was sold at an average price of $959.00, for a total value of $793,093.00. Following the sale, the director now directly owns 1,382 shares of the company’s stock, valued at $1,325,338. The disclosure for this sale can be found here. Insiders sold 11,022 shares of company stock valued at $10,552,991 in the last ninety days. Insiders own 8.83% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN traded down $0.78 during trading on Wednesday, reaching $906.54. 369,734 shares of the company traded hands, compared to its average volume of 489,809. Regeneron Pharmaceuticals, Inc. has a 1-year low of $684.80 and a 1-year high of $998.33. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.94 and a current ratio of 5.69. The stock’s 50 day moving average price is $951.41 and its two-hundred day moving average price is $893.20. The company has a market cap of $99.50 billion, a price-to-earnings ratio of 26.17, a P/E/G ratio of 2.59 and a beta of 0.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, beating analysts’ consensus estimates of $10.73 by $1.13. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The firm had revenue of $3.43 billion for the quarter, compared to analysts’ expectations of $3.29 billion. During the same period in the prior year, the business posted $10.96 earnings per share. The business’s revenue was up .6% compared to the same quarter last year. As a group, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 38.8 EPS for the current year.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.